2m 2m 2m 2m 2m 2m 2m
IGC Pharma (IGC)
NYSE
$0.27+$0.009 (+3.40%)
Price as of Jun 23, 2026 7:51 PM EDT- $26.7MMarket Cap
- -14.07%1-Year Change
- BiotechnologyIndustry
IGC Pharma (IGC)
$0.27+$0.009 (+3.40%)
Annual
Quarterly
12/31/2025 | 03/31/2024 | 03/31/2023 | 03/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 869,000 -35.39% | 1.3M +47.64% | 911,000 +129.47% | 397,000 -55.79% | |
Cost of Revenue | 572,000 -6.54% | 612,000 +30.49% | 469,000 +131.03% | 203,000 -74.14% | |
Gross Profit | 297,000 -59.48% | 733,000 +65.84% | 442,000 +127.84% | 194,000 +71.68% | |
Sales and Marketing Expense | 4.1M -39.02% | 6.8M -20.98% | 8.6M -35.66% | 13.3M +68.08% | |
Research and Development Expense | -3.9M +3.92% | -3.8M +9.01% | -3.5M -248.54% | 2.3M +150.81% | |
Depreciation and Amortization Expense | 324,000 -49.14% | 637,000 -3.04% | 657,000 +0.92% | 651,000 +36.19% | |
Total Operating Expenses | 4.1M -39.02% | 6.8M -20.98% | 8.6M -35.66% | 13.3M +68.08% | |
Operating Profit | -7.7M -20.95% | -9.8M -15.32% | -11.6M -25.00% | -15.4M +76.85% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -4,000 -20.00% | -5,000 0.00% | -5,000 0.00% | -5,000 +66.67% | |
Interest Income and Expense and Net | -4,000 -20.00% | -5,000 0.00% | -5,000 -200.00% | 5,000 +66.67% | |
Total Nonoperating Income and Expense | 3.6M +2,416.78% | 143,000 +120.00% | 65,000 -85.90% | 461,000 +462.20% | |
Income before Taxes | -4.1M -68.11% | -13.0M +12.98% | -11.5M -23.38% | -15.0M +70.42% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | 0 -100.00% | 3.4M N/A | 0 -100.00% | 833,000 N/A | |
Net Income | -4.1M -68.11% | -13.0M +12.98% | -11.5M -23.38% | -15.0M +70.42% | |
Net Income from Continuing Operations Applicable to Common | -4.1M -68.11% | -13.0M +12.98% | -11.5M -23.38% | -15.0M +70.42% | |
Basic EPS and Net Income | -0.05 N/A | N/A N/A | N/A N/A | N/A N/A | |
Diluted EPS and Net Income | -0.05 N/A | N/A N/A | N/A N/A | N/A N/A | |
Basic Weighted Average Shares | 88.9M +51.01% | 58.8M +11.91% | 52.6M +5.17% | 50.0M +19.13% | |
Diluted Weighted Average Shares | 88.9M +51.01% | 58.8M +11.91% | 52.6M +5.17% | 50.0M +19.13% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 900,000 -24.87% | 1.2M -62.52% | 3.2M -69.45% | 10.5M -28.10% | |
Short-Term Investments | 38,000 N/A | 0 -100.00% | 154,000 N/A | 0 -100.00% | |
Cash and Cash Equivalents and Short-Term Investments | 938,000 -21.70% | 1.2M -64.24% | 3.4M -67.97% | 10.5M -28.49% | |
Total Current Assets | 1.8M -51.69% | 3.7M -42.70% | 6.5M -57.21% | 15.1M -35.74% | |
Accumulated Depreciation | 1.7M -31.61% | 2.4M +26.14% | 1.9M -39.88% | 3.2M +13.62% | |
Property and Plant and Equipment and Net | 2.1M -42.06% | 3.7M -55.01% | 8.2M -12.80% | 9.4M -13.11% | |
Total Long-Term Assets | 7.9M +27.84% | 6.2M -42.15% | 10.7M -8.62% | 11.7M -5.08% | |
Total Assets | 9.7M -1.92% | 9.9M -42.36% | 17.2M -35.98% | 26.8M -25.18% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 6,000 0.00% | 6,000 0.00% | 6,000 +100.00% | 3,000 -99.01% | |
Total Current Liabilities | 2.2M -7.86% | 2.3M +23.29% | 1.9M -22.24% | 2.4M +3.08% | |
Total Long-Term Debt | 131,000 -4.38% | 137,000 -2.84% | 141,000 -2.08% | 144,000 -47.83% | |
Total Long-Term Liabilities | 133,000 -44.81% | 241,000 -34.69% | 369,000 -26.35% | 501,000 -28.02% | |
Total Liabilities | 2.3M -11.31% | 2.6M +13.85% | 2.3M -22.94% | 2.9M -3.98% | |
Retained Earnings | -124.9M +9.88% | -113.7M +12.91% | -100.7M +12.91% | -89.2M +20.25% | |
Total Stockholders Equity | 7.4M +1.39% | 7.3M -50.90% | 14.9M -37.59% | 23.9M -27.17% | |
Total Shares Outstanding | 95.0M +42.50% | 66.7M +25.65% | 53.1M +3.96% | 51.1M +6.75% | |
Cash Flow | |||||
Cash from Operating Activities | -4.7M -9.21% | -5.2M -26.22% | -7.0M -5.56% | -7.5M -30.91% | |
Capital Expenditures | 49,000 -64.49% | 138,000 -55.48% | 310,000 +49.76% | 207,000 -85.92% | |
Cash from Investing Activities | -22,000 -93.06% | -317,000 +34.89% | -235,000 -68.33% | -742,000 -121.91% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 5.2M +48.27% | 3.5M +3,424.00% | 100,000 -97.59% | 4.1M -71.80% | |
Financials Ratio | |||||
Gross Margin | 34.18% -37.29% | 54.50% +12.33% | 48.52% -0.71% | 48.87% +288.34% | |
Operating Margin | -891.25% +22.35% | -728.48% -42.65% | -1,270.14% -67.32% | -3,886.15% +300.02% | |
Return on Assets | -42.28% -55.97% | -96.01% +83.63% | -52.29% +9.16% | -47.90% +76.27% | |
Return on Equity | -56.24% -51.91% | -116.95% +97.20% | -59.30% +11.96% | -52.97% +78.37% | |
Revenue Growth | -35.39% -174.29% | 47.64% -63.20% | 129.47% +332.07% | -55.79% -28.42% | |
Current Ratio | 0.83 -47.57% | 1.58 -53.52% | 3.41 -44.97% | 6.19 -37.67% | |
Cash Ratio | 0.42 -18.48% | 0.51 -69.59% | 1.68 -60.70% | 4.29 -30.25% | |
Debt-to-Equity Ratio | 0.02 -5.13% | 0.02 +96.97% | 0.010 +59.68% | 0.006 -64.97% | |
Debt-to-Assets Ratio | 0.01 -2.08% | 0.01 +67.44% | 0.009 +56.36% | 0.006 -66.05% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow